Xilio Therapeutics, Inc. Stock Price, News & Analysis

Xilio Therapeutics (Nasdaq: XLO) announced the grant of a non-qualified stock option for 55,000 shares to Kevin Brennan, the newly appointed Senior Vice President of Finance and Accounting, effective April 1, 2023. This stock option has an exercise price of $3.17 per share, matching the closing price on March 31, 2023, and will vest in increments over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize Mr. Brennan's role in the company. Xilio is focused on developing tumor-activated immuno-oncology therapies to improve treatment outcomes for cancer patients.

Xilio Therapeutics, Inc. (Nasdaq: XLO) reported progress in its clinical pipeline and financial results for 2022. The company ended 2022 with $120.4 million in cash, expected to fund operations into Q2 2024. XTX202, a tumor-activated IL-2, showed promising early results in a Phase 1 trial, with plans to initiate a Phase 2 trial in April 2023. XTX301 and XTX101 are also in development, with preliminary data anticipated in 2023. However, net losses increased to $88.2 million for the year, up from $75.8 million in 2021, driven by R&D expenses, which grew to $59.2 million.

Xilio Therapeutics, a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, announced its participation in two investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 6, 2023, at 9:10 a.m. ET, while the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, with a virtual presentation at 4:00 p.m. ET. Investors can access live webcasts on the Xilio Therapeutics website, with replays available for 30 days post-event. The company utilizes a proprietary platform to develop therapies aimed at improving cancer treatment outcomes without systemic side effects.

Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET. The live presentation will be available on the company's website, with a replay accessible for 30 days post-event. Xilio is focused on developing tumor-activated therapies aimed at improving cancer treatment outcomes while minimizing side effects. Their innovative approach utilizes proprietary technology to target anti-tumor activity specifically within the tumor microenvironment, with multiple programs currently in clinical and preclinical stages.

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced that CEO René Russo will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 3:55 p.m. ET in New York. Investors can access a live webcast of the presentation through the Investors & Media section of the Xilio Therapeutics website. A recorded version will be available for 30 days post-event. The company focuses on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes while reducing systemic side effects. Xilio is advancing multiple clinical and preclinical programs in this innovative area.

Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a live virtual program on December 1, 2022, at 12:30 p.m. ET to discuss its clinical-stage molecule, XTX301, an engineered IL-12 aimed at treating immunologically 'cold' tumors. Dr. Diwakar Davar from UPMC Hillman Cancer Center will explain the significance of IL-12 in stimulating anti-tumor immunity and the differences between cold and hot tumors. Xilio executives will also outline the Phase 1 trial for XTX301 and its anticipated timeline. The event will include a Q&A session.

Xilio Therapeutics (Nasdaq: XLO) reported significant progress in its clinical-stage pipeline, showcasing tumor-activated therapies, XTX202 and XTX301. The ongoing Phase 1 trial for XTX202 has successfully reached a target dose of 1 mg/kg, showing increased CD8+ effector and NK cells without vascular leak syndrome. XTX301 received FDA IND clearance, with patient enrollment expected in early 2023. The company reported $139.1 million in cash as of September 30, 2022, which is projected to last until Q2 2024, despite a net loss of $19.8 million for Q3 2022.

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced its participation in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on November 11, 2022, at 1:40 p.m. ET. The event can be accessed via live webcast in the Investors & Media section of its website, with a replay available for 30 days post-presentation. Xilio focuses on developing tumor-activated immuno-oncology therapies, using its GPS platform to create biologics targeting the tumor microenvironment, aiming for enhanced anti-tumor activity. Key product candidates include XTX101 and XTX202.